Tema Cardiovascular and Metabolic ETF — News

$36.5516 USD

$0.16 (0.43%)

Source	Headline
	Weight Loss ETFs Poised to Rally as Medicare Greenlights GLP-1 Coverage Medicare's new GLP-1 coverage could expand access to weight-loss drugs, making ETFs a diversified way to tap growth across the obesity treatment market. zacks.com - 2026-07-01 09:16:09
	Tema ETFs Exceeds $5bn in AUM After Three Years NEW YORK--(BUSINESS WIRE)--Tema ETFs (“Tema”), a leader in institutional-quality and actively managed exchange-traded funds, has surpassed $5 billion in assets under management (AUM) three years since listing its first product with $5 million.1 Tema has grown AUM by more than $3 billion in the first five months of 2026,2 underscoring strong momentum and growing adoption from financial advisors and professional investors. businesswire.com - 2026-06-15 09:51:00
	Inside the GLP-1 Boom: ETF Picks for the Obesity Drug Market GLP-1 drugs are reshaping healthcare and consumer markets. These ETFs offer targeted exposure to the booming obesity-drug trend. zacks.com - 2026-06-10 13:01:19
	GLP-1 Drug Giants Race to Go Global With Their Obesity Pills: ETFs to Gain Eli Lilly and Novo Nordisk are accelerating global obesity pill launches as rising GLP-1 demand puts weight-loss ETFs in focus. zacks.com - 2026-05-19 15:31:07